Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep;146(3):588-595.
doi: 10.1016/j.ygyno.2017.07.003. Epub 2017 Jul 11.

Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival

Casey M Cosgrove  1 , David E Cohn  1 , Heather Hampel  2 , Wendy L Frankel  3 , Dan Jones  3 , Joseph P McElroy  4 , Adrian A Suarez  3 , Weiqiang Zhao  3 , Wei Chen  3 , Ritu Salani  1 , Larry J Copeland  1 , David M O'Malley  1 , Jeffrey M Fowler  1 , Ahmet Yilmaz  3 , Alexis S Chassen  1 , Rachel Pearlman  2 , Paul J Goodfellow  5 , Floor J Backes  1
Affiliations

Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival

Casey M Cosgrove et al. Gynecol Oncol. 2017 Sep.

Abstract

Objectives: To determine the relationship between mismatch repair (MMR) classification and clinicopathologic features including tumor volume, and explore outcomes by MMR class in a contemporary cohort.

Methods: Single institution cohort evaluating MMR classification for endometrial cancers (EC). MMR immunohistochemistry (IHC)±microsatellite instability (MSI) testing and reflex MLH1 methylation testing was performed. Tumors with MMR abnormalities by IHC or MSI and MLH1 methylation were classified as epigenetic MMR deficiency while those without MLH1 methylation were classified as probable MMR mutations. Clinicopathologic characteristics were analyzed.

Results: 466 endometrial cancers were classified; 75% as MMR proficient, 20% epigenetic MMR defects, and 5% as probable MMR mutations. Epigenetic MMR defects were associated with advanced stage, higher grade, presence of lymphovascular space invasion, and older age. MMR class was significantly associated with tumor volume, an association not previously reported. The epigenetic MMR defect tumors median volume was 10,220mm3 compared to 3321mm3 and 2,846mm3, for MMR proficient and probable MMR mutations respectively (P<0.0001). Higher tumor volume was associated with lymph node involvement. Endometrioid EC cases with epigenetic MMR defects had significantly reduced recurrence-free survival (RFS). Among advanced stage (III/IV) endometrioid EC the epigenetic MMR defect group was more likely to recur compared to the MMR proficient group (47.7% vs 3.4%) despite receiving similar adjuvant therapy. In contrast, there was no difference in the number of early stage recurrences for the different MMR classes.

Conclusions: MMR testing that includes MLH1 methylation analysis defines a subset of tumors that have worse prognostic features and reduced RFS.

Keywords: DNA mismatch repair; Endometrial cancer; Epigenomics; Lymph node excision; Lynch syndrome.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest disclosure: None of the authors have a conflict of interest to disclose.

Figures

Figure 1
Figure 1
MMR testing algorithm and class distribution.
Figure 2
Figure 2
A) Tumor volume by MMR class for all histologies and for endometrioid histology only. B) Tumor volume and lymph node status for all endometrioid cases with lymphadenectomy performed and by epigenetic MMR defective and MMR proficient tumors.
Figure 3
Figure 3
A) Recurrence-free survival by MMR class for subjects with endometrioid histology tumors. B) Recurrence and adjuvant therapy use by stage and MMR class.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. - PubMed
    1. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ. Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215; Bethesda, MD: 2007. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001.
    1. Lancaster JM, Powell CB, Chen LM, Richardson DL. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015;136:3–7. - PubMed
    1. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, De La Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. International Journal of Cancer. 1999;81:214–218. - PubMed
    1. Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology. 2005;129:415–421. - PubMed

Publication types

MeSH terms